Report of Foreign Issuer (6-k)
08 Novembre 2016 - 3:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November, 2016
Commission File Number: 001-16174
Teva Pharmaceutical Industries Ltd.
|
(Translation of registrants name into English)
|
|
Israel
|
(Jurisdiction of incorporation or organization)
|
|
5 Basel Street, P.O. Box 3190
Petach Tikva 4951033 Israel
|
(Address of principal executive office)
|
|
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: [
x
] Form 20-F [
] Form 40-F
|
|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [
]
|
|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [
]
|
|
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: [
] Yes [
x
] No
|
|
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
n/a
|
|
SIGNATURES
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
Teva Pharmaceutical Industries Ltd.
|
|
|
|
Date: 11/08/2016
|
By:
|
Eyal Desheh
|
|
Name:
|
Eyal Desheh
|
|
Title:
|
Group EVP & CFO
|
|
|
|
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Teva Announces Appointment of new Chief Legal Officer
|
|
|
|
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Août 2023 à Août 2024